News | April 24, 2025
Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
More than 40 types of Amyloid proteins are discovered till date
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
This curated geriatric care package - Varishtha Aarogya Vardaan -- includes a comprehensive range of essential blood tests specifically curated for seniors.
Subscribe To Our Newsletter & Stay Updated
